60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Core Viewpoint - 60 Degree Pharmaceuticals, Inc. will implement a one-for-four (1:4) reverse stock split to comply with Nasdaq's minimum bid price requirement, effective January 20, 2026 [1][2] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 5,148,767 to about 1,287,192 [5] - All issued and outstanding shares, options, restricted stock awards, warrants, and other securities will be adjusted accordingly, with no fractional shares issued [4] - The par value of the Common Stock will remain unchanged at $0.0001 per share, and the authorized number of shares will not change [4] Group 2: Approval Process - Stockholders approved the reverse split proposal at a special meeting on October 8, 2025, allowing the board to file an amendment to effect the split [3] - The board officially approved the reverse split on December 17, 2025, and the amendment has been filed with the Secretary of State of Delaware [3] Group 3: Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA, in 2018 [6] - The company is headquartered in Washington, D.C., with a subsidiary in Australia and collaborates with prominent research organizations [6]